| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:1569-1576.)
© 2007 American Heart Association, Inc.
Molecular Cardiology |
From the Department of Clinical Genetics (Z.A.B., M.A., I.v.L., M.M.A.M.M.), and Heart Failure Research Center (A.V.P., A.A.M.W.), Academic Medical Center, University of Amsterdam, The Netherlands; Departments of Cardiology (M.P.v.d.B., A.C.P.W.), Clinical Genetics (J.P.v.T.), and Pediatric Cardiology (M.T.E.B.-B.), University Medical Center, University of Groningen, The Netherlands, and Interuniversity Cardiology Institute of The Netherlands (M.P.v.d.B., A.A.M.W.).
Correspondence to Dr Zahurul A. Bhuiyan, Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam, The Netherlands. E-mail z.a.bhuiyan{at}amc.uva.nl
Received April 26, 2007; accepted July 20, 2007.
Background— Catecholaminergic polymorphic ventricular tachycardia is a disease characterized by ventricular arrhythmias elicited exclusively under adrenergic stress. Additional features include baseline bradycardia and, in some patients, right ventricular fatty displacement. The clinical spectrum is expanded by the 2 families described here.
Methods and Results— Sixteen members from 2 separate families have been clinically evaluated and followed over the last 15 years. In addition to exercise-related ventricular arrhythmias, they showed abnormalities in sinoatrial node function, as well as atrioventricular nodal function, atrial fibrillation, and atrial standstill. Left ventricular dysfunction and dilatation was present in several affected individuals. Linkage analysis mapped the disease phenotype to a 4-cM region on chromosome 1q42-q43. Conventional polymerase chain reaction–based screening did not reveal a mutation in either the Ryanodine receptor 2 gene (RYR2) or ACTN2, the most plausible candidate genes in the region of interest. Multiplex ligation-dependent probe amplification and long-range polymerase chain reaction identified a genomic deletion that involved RYR2 exon-3, segregated in all the affected family members (n=16) in these 2 unlinked families. Further investigation revealed that the genomic deletion occurred in both families as a result of Alu repeat–mediated polymerase slippage.
Conclusions— This is the first report on a large genomic deletion in RYR2, which leads to extended clinical phenotypes (eg, sinoatrial node and atrioventricular node dysfunction, atrial fibrillation, atrial standstill, and dilated cardiomyopathy). These features have not previously been linked to RYR2.
This article has been cited by other articles:
![]() |
A. Medeiros-Domingo, Z. A. Bhuiyan, D. J. Tester, N. Hofman, H. Bikker, J. P. van Tintelen, M. M.A.M. Mannens, A. A.M. Wilde, and M. J. Ackerman The RYR2-Encoded Ryanodine Receptor/Calcium Release Channel in Patients Diagnosed Previously With Either Catecholaminergic Polymorphic Ventricular Tachycardia or Genotype Negative, Exercise-Induced Long QT Syndrome A Comprehensive Open Reading Frame Mutational Analysis. J. Am. Coll. Cardiol., November 24, 2009; 54(22): 2065 - 2074. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' Europace, July 1, 2009; 11(7): 860 - 885. [Full Text] [PDF] |
||||
![]() |
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst CHAPTER 29 Atrial Fibrillation ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |